
Myomo (MYO) Stock Forecast & Price Target
Myomo (MYO) Analyst Ratings
Bulls say
Myomo Inc. has demonstrated a robust growth trajectory in its reimbursement pipeline, which increased to 1,611 units from 1,482 in Q1 and 1,389 in Q4 of the previous year. This upward trend indicates a strengthening demand for its myoelectric orthotics and highlights the company's expanding market presence, particularly in the orthotics and prosthetics sector. Additionally, the recent Medicare ruling by the CMS to include MyoPro under Medicare Part B benefits significantly broadens the company's potential market, aligning it with a large and crucial revenue stream.
Bears say
Myomo Inc has revised its 2025 revenue guidance downward to a range of $40 – 42 million, significantly lower than the previously anticipated $50 – 53 million. The company's marketing and pipeline performance have also underperformed, leading to decreased lead quality and conversion rates. Additionally, the backlog of insurance-authorized orders has declined to 230, down from 249 in the previous quarter and 272 at the end of the prior fiscal year.
This aggregate rating is based on analysts' research of Myomo and is not a guaranteed prediction by Public.com or investment advice.
Myomo (MYO) Analyst Forecast & Price Prediction
Start investing in Myomo (MYO)
Order type
Buy in
Order amount
Est. shares
0 shares